Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: A comparison of atorvastatin and simvastatin

Biochimica et Biophysica Acta - Lipids and Lipid Metabolism

Volumn 1389, Issue 3, 1998, Pages 213-221

  Bergstrom, James D ^a   Bostedor, Richard G ^a   Rew, Deborah J ^a   Geissler, Wayne M ^a   Wright, Samuel D ^a   Chao, Yu Sheng ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cholesterol lowering drug; Cholesterol synthesis; HepG2 cell; HMG CoA reductase inhibitor

Indexed keywords

ATORVA; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; SIMVA; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CHOLESTEROL LIVER LEVEL; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHOLESTEROL; ENZYME INDUCTION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KINETICS; LIVER; LIVER NEOPLASMS; MALE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIMVASTATIN; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0032559306     PISSN: 00052760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2760(97)00182-3     Document Type: Article

References (40)

1. [1] A.W. Alberts, Atherosclerosis Reviews 18 (1988) 123-131.
2. [2] M.S. Brown, J.L. Goldstein, J. Lipid Res. 21 (1980) 505-517.
3. [3] S. Balasubramaniam, J.L. Goldstein, M.S. Brown, Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 1421-1425.
4. [4] J.D. Bergstrom, G.A. Wong, P.A. Edwards, J. Edmond, J. Biol. Chem. 259 (1984) 14548-14553.
5. [5] P.T. Kovanen, D.W. Bilheimer, J.L. Goldstein, J.J. Jaramillo, M.S. Brown, Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 1194-1198.
6. [6] P.T.S. Ma, G. Gil, T.C. Sudhof, D.W. Bilheimer, J.L. Goldstein, M.S. Brown, Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 3499-3503.
7. [7] J.L. Goldstein, M.S. Brown, Nature 343 (1990) 425-430.
8. [8] L. Liscum, K.L. Luskey, D.J. Chin, Y.K. Ho, J.L. Goldstein, M.S. Brown, J. Biol. Chem. 258 (1983) 8450-8455.
9. [9] J.R. Faust, K.L. Luskey, D.J. Chin, J.L. Goldstein, M.S. Brown, Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 5205-5209.
10. [10] S.M. Grundy, New Eng. J. Med. 319 (1988) 24-33.
11. [11] G.F. Watts, M.H. Cummings, M. Umpleby, J.R. Quney, R. Naoumova, G.R. Thompson, P.H. Sonksen, Eur. J. Clin. Invest. 25 (1995) 559-567.
12. [12] K. Conde, M. Vergara-Jimenez, B.R. Krause, R.S. Newton, M.L. Fernandez, J. Lipid Res. 37 (1996) 2372-2382.
13. [13] B. Khan, H.G. Wilcox, M. Heimberg, Biochem. J. 259 (1989) 807-816.
14. [14] D.R. Illingworth, J.A. Tobert, Clin. Ther. 16 (1994) 366-385.
15. [15] R.G. Bakker-Arkema, M.H. Davidson, R.J. Goldstein, J. Davignon, J.L. Isaacsohn, S.R. Weiss, L.M. Keilson, W.V. Brown, V.T. Miller, L.J. Shurzinske, D.M. Black, J. Am. Med. Assoc. 275 (1996) 128-133.
16. [16] T.M.A. Bocan, M.J. Mazur, S.B. Mueller, E.Q. Brown, D.R. Sliskovic, P.M. O'Brien, M.W. Creswell, H. Lee, P.D. Uhlendorf, B.D. Roth, R.S. Newton, Atherosclerosis 111 (1994) 127-142.
17. [17] B.R. Krause, R. Bousley, K. Kieft, R. Stanfield, R.S. Newton, FASEB J. 7 (1993) A567.
18. [18] B.R. Krause, R.S. Newton, Atherosclerosis 117 (1995) 237-244.
19. [19] B.J. Auerbach, B.R. Krause, C.L. Bisgaier, R.S. Newton, Atherosclerosis 115 (1994) 173-180.
20. [20] R.S. Newton, European Atherosclerosis Society 66th Annual Meeting, Abstract Book, Giovanni Lorenzi Medical Foundation, Milan and Houston, 1996, p. 31.
21. [21] D.D. Cilla Jr., D.M. Gibson, L.R. Whitfield, A.J. Sedman, J. Clin. Pharmacol. 36 (1996) 604-609.
22. [22] D.M. Gibson, N.J. Bron, A. Richens, N.J. Hounslow, A.J. Sedman, L.R. Whitfield, J. Clin. Pharmacol. 36 (1996) 242-246.
23. [23] L.L. Radulovic, D.D. Cilla, E.L. Posvar, A.J. Sedman, L.R. Whitfield, J. Clin. Pharmacol. 35 (1995) 990-994.
24. [24] E.L. Posvar, L.L. Radulovic, D.D. Cilla Jr., L.R. Whitfield, A.J. Sedman, J. Clin. Pharmacol. 36 (1996) 728-731.
25. [25] P.J. Pentikainen, M. Saraheimo, J.I. Schwartz, R.D. Amin, M.S. Schwartz, F. Brunner-Ferber, J.D. Rogers, J. Clin. Pharmacol. 32 (1992) 136-140.
26. [26] M.H. Davidson, E.A. Stein, C.A. Dujovne, D.B. Hunninghake, S.R. Weiss, R.H. Knopp, D.R. Illingworth, Y.B. Mitchel, M.R. Melino, R.V. Zupkis, M.R. Dobrinska, R.D. Amin, J.A. Tobert, Am J. Cardiol. 79 (1997) 38-42.
27. [27] T. Heinonen, E. Stein, J. Issacsohn, M. Davidson, J. Davignon, M. Montigny, G. Tremblay, A. Edwards, D. Hunninghake, T. Ooi, H. Schrott, R. Knopp, P.J. Lupien, C. Gagne, J. McKenney, J. Zavoral, A. Sniderman, J. Frohlich, L. Leiter, M. McQueen, G. Steiner, D. Gaudet, L. Keilson, C. Dujovne, R. McLain, D. Black, European Atherosclerosis Society 66th Annual Meeting, Abstract Book, Giovanni Lorenzi Medical Foundation, Milan and Houston, 1996, p. 214.
28. [28] J.I. Germershausen, V.M. Hunt, R.G. Bostedor, P.J. Bailey, J.D. Karkas, A.W. Alberts, Biochem. Biophys. Res. Comm. 158 (1989) 667-675.
29. [29] J. Edmond, J. Biol. Chem. 249 (1974) 72-80.
30. [30] R.D. Tanaka, A.C. Li, A.M. Fogelman, P.A. Edwards, J. Lipid Res. 27 (1986) 261-273.
31. [31] P.A. Edwards, H. Muroya, R.C. Gould, J. Lipid Res. 13 (1972) 396-401.
32. [32] K.M. Cianflone, Z. Yasruel, M.A. Rodriguez, D. Vas, A.D. Sniderman, J. Lipid Res. 31 (1990) 2045-2055.
33. [33] W. Qin, J. Infante, S.-R. Wang, R. Infante, Biochim. Biophys. Acta 1127 (1992) 57-66.
34. [34] S. Furukawa, T. Hirano, Biochim. Biophys. Acta 1170 (1993) 32-37.
35. [35] R. Sato, T. Imanaka, T. Takano, Biochim. Biophys. Acta 1042 (1990) 36-41.
36. [36] X. Wu, N. Sakata, E. Lui, H.N. Ginsberg, J. Biol. Chem. 269 (1994) 12375-12382.
37. [37] A. Kaptein, L. Roodenburd, H.M.G. Princen, Biochem. J. 278 (1991) 557-564.
38. [38] A. Kaptein, E.C.M. de Wit, H.M.G. Princen, Biochim. Biophys. Acta 1213 (1994) 349-356.
39. [39] I. Zabin, K. Bloch, J. Biol. Chem. 192 (1951) 261-266.
40. [40] B.R. Krause, R.S. Newton, Atherosclerosis 117 (1995) 237-244.